Osteoboost Health, Inc. has officially launched Osteoboost, the first and only FDA-cleared prescription wearable device for individuals with low bone density, marking a major advancement for more than 60 million Americans at risk. As aging populations embrace a lifestyle of strength and independence, Osteoboost introduces a novel, preventative approach to bone health. This at-home device delivers targeted vibration therapy to the spine and hips, the most common sites for osteoporotic fractures, helping to reduce fracture risk before osteoporosis develops. Clinically validated in a gold-standard, double-blinded, placebo-controlled trial, Osteoboost slowed bone density and strength loss by up to 85% in the spine and 55% in the hip among postmenopausal women with osteopenia.
Cleared through the FDA De Novo pathway and designated a Breakthrough Device, Osteoboost combines patented medical-grade vibration technology with ease of use—requiring just 30 minutes of wear daily. Led by CEO Laura Yecies, a veteran entrepreneur, Osteoboost addresses a major treatment gap in bone care, as current therapies typically begin only after a fracture occurs. Already prescribed by over 1,000 physicians nationwide, the device has gained rapid traction among leading medical centers and practitioners.
Also Read: J&J Unveils ETHICON™ 4000 Stapler to Elevate Surgical Precision and Staple Security.
To improve access, Osteoboost is now available via online consultations in partnership with Beluga Health, enabling patients to receive prescriptions from their own physician or through a streamlined telehealth process. Backed by AARP, Harvard Business School Angels, and Esplanade Healthtech Ventures, Osteoboost Health is redefining the future of proactive bone health management.
